Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers von Hopkins, Ashley M, Rowland, Andrew, Kichenadasse, Ganessan, Wiese, Michael D, Gurney, Howard, McKinnon, Ross A, Karapetis, Chris S, Sorich, Michael J

Volltext

Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials von Sorich, Michael J., Rowland, Andrew, Karapetis, Christos S., Hopkins, Ashley M.

Volltext

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift von Hopkins, Ashley M, Logan, Jessica M, Kichenadasse, Ganessan, Sorich, Michael J

Volltext

Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab von Hopkins, Ashley M, Kichenadasse, Ganessan, Karapetis, Christos S, Rowland, Andrew, Sorich, Michael J

Volltext

Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab von Hopkins, Ashley M., Kichenadasse, Ganessan, Karapetis, Christos S., Rowland, Andrew, Sorich, Michael J.

Volltext

Health Disinformation Use Case Highlighting the Urgent Need for Artificial Intelligence Vigilance: Weapons of Mass Disinformation von Menz, Bradley D, Modi, Natansh D, Sorich, Michael J, Hopkins, Ashley M

Volltext

Patient‐reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy von Hopkins, Ashley M., Wagner, Jordan, Kichenadasse, Ganessan, Modi, Natansh, Rowland, Andrew, Sorich, Michael J.

Volltext

Potential of Large Language Models as Tools Against Medical Disinformation—Reply von Hopkins, Ashley M, Menz, Bradley D, Sorich, Michael J

Volltext

Ritonavir may prolong sedation but is unlikely to increase the risk of respiratory arrest in patients requiring intravenous midazolam for procedural sedation von Arsanious, Jason, Rowland, Angela, Sorich, Michael J, Hopkins, Ashley M, Alfred, Sam, Rowland, Andrew

Volltext

Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab von Hopkins, Ashley M, Kichenadasse, Ganessan, Garrett-Mayer, Elizabeth, Karapetis, Christos S, Rowland, Andrew, Sorich, Michael J

Volltext

Response to Mazzaschi and Buti von Hopkins, Ashley M., Sorich, Michael J.

Volltext

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability von Hopkins, Ashley M, Rowland, Andrew, Sorich, Michael J

Volltext

Patient‐Reported Outcomes Predict Progression‐Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib von Badaoui, Sarah, Kichenadasse, Ganessan, Rowland, Andrew, Sorich, Michael J., Hopkins, Ashley M.

Volltext

Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis von Shahnam, Adel, Nindra, Udit, Desai, Jayesh, Hui, Rina, Buyse, Marc, Hopkins, Ashley M, Sorich, Michael J

Volltext

Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150 von Hopkins, Ashley M., Kichenadasse, Ganessan, McKinnon, Ross A., Abuhelwa, Ahmad Y., Logan, Jessica M., Badaoui, Sarah, Karapetis, Christos S., Rowland, Andrew, Sorich, Michael J.

Volltext

Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors von Hopkins, Ashley M., Kichenadasse, Ganessan, McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J.

Volltext

Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials von Hopkins, Ashley M., Badaoui, Sarah, Kichenadasse, Ganessan, Karapetis, Christos S., McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J.

Volltext

Regarding the Article by Rugo et al von Badaoui, Sarah, Rowland, Andrew, Sorich, Michael J., Hopkins, Ashley M.

Volltext

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials von Li, Lee X, Cappuzzo, Federico, Matos, Ignacio, Socinski, Mark A, Hopkins, Ashley M, Sorich, Michael J

Volltext

Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients von Ruanglertboon, Warit, Sorich, Michael J., Rowland, Andrew, Hopkins, Ashley M.

Volltext